{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T08:39:06Z","timestamp":1789202346017,"version":"build-2803163510"},"reference-count":38,"publisher":"The Journal of Rheumatology","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2016,8]]},"abstract":"<jats:sec>\n                    <jats:title>Objective.<\/jats:title>\n                    <jats:p>Rituximab (RTX) has been used successfully for the treatment of severe Jo1 antibody-associated antisynthetase syndrome. The aim of this retrospective study was to evaluate the effect of RTX in severe Jo1 antisynthetase syndrome and determine predictive factors for response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods.<\/jats:title>\n                    <jats:p>There were 61 patients with Jo1 antisynthetase syndrome identified; 18 of these received RTX. One patient was lost to followup. The remaining 17 patients and 30 out of 43 patients who were treated with conventional immunosuppressive (IS) drugs were followed for a mean of 35 months and 84 months, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results.<\/jats:title>\n                    <jats:p>\n                      Polymyositis\/dermatomyositis (95%) and interstitial lung disease (ILD; 66%) were the dominant clinical manifestations. Detection of anti-Ro52 antibodies (43%) was significantly associated with acute-onset ILD (p = 0.016) with O\n                      <jats:sub>2<\/jats:sub>\n                      dependency, and patients with high concentrations of anti-Ro52 (20%) had the highest risk (p = 0.0005). Sixteen out of 18 patients (89%) showed a fast and marked response to RTX. Among those patients who were highly positive for anti-Ro52, response to RTX was seen in 7 out of 7 cases (100%), but no response to cyclophosphamide (n = 4), cyclosporine A (n = 3), azathioprine (n = 9), methotrexate (n = 5), or leflunomide (n = 2) was observed. One patient treated with RTX died of pneumonia.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion.<\/jats:title>\n                    <jats:p>RTX is effective in the treatment of severe forms of Jo1 antisynthetase syndrome. In our retrospective study, the presence of high anti-Ro52 antibody concentrations predicts severe acute-onset ILD and nonresponse to IS drugs. In contrast to conventional IS, RTX is equally effective in patients with Jo1 antisynthetase syndrome, independent of their anti-Ro52 antibody status.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3899\/jrheum.150844","type":"journal-article","created":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T23:49:22Z","timestamp":1464824962000},"page":"1566-1574","source":"Crossref","is-referenced-by-count":129,"title":["Rituximab in the Treatment of Jo1 Antibody\u2013associated Antisynthetase Syndrome: Anti-Ro52 Positivity as a Marker for Severity and Treatment Response"],"prefix":"10.3899","volume":"43","author":[{"given":"Jutta","family":"Bauhammer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Blank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina","family":"Max","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanns-Martin","family":"Lorenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dietmar","family":"Krause","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Fiehn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2016,6,1]]},"reference":[{"key":"2018112909360433000_43.8.1566.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2014.01.022"},{"key":"2018112909360433000_43.8.1566.2","doi-asserted-by":"publisher","DOI":"10.1007\/s00393-013-1196-8"},{"key":"2018112909360433000_43.8.1566.3","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-013-0335-1"},{"key":"2018112909360433000_43.8.1566.4","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21895"},{"key":"2018112909360433000_43.8.1566.5","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2006.069237"},{"key":"2018112909360433000_43.8.1566.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2009.02.010"},{"key":"2018112909360433000_43.8.1566.7","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2249.1997.4081308.x"},{"key":"2018112909360433000_43.8.1566.8","doi-asserted-by":"publisher","DOI":"10.1136\/ard.60.2.116"},{"key":"2018112909360433000_43.8.1566.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2011.09.008"},{"key":"2018112909360433000_43.8.1566.10","doi-asserted-by":"publisher","DOI":"10.1080\/08916930600623791"},{"key":"2018112909360433000_43.8.1566.11","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-009-0884-9"},{"key":"2018112909360433000_43.8.1566.12","first-page":"1369","article-title":"Efficacy of rituximab in refractory polymyositis","volume":"32","author":"Lambotte","year":"2005","journal-title":"J Rheumatol"},{"key":"2018112909360433000_43.8.1566.13","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.045898"},{"key":"2018112909360433000_43.8.1566.14","first-page":"887","article-title":"Clinical outcome following B cell depletion therapy in eight patients with refractory idiopathic inflammatory myopathy","volume":"26","author":"Sultan","year":"2008","journal-title":"Clin Exp Rheumatol"},{"key":"2018112909360433000_43.8.1566.15","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep157"},{"key":"2018112909360433000_43.8.1566.16","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-009-0859-x"},{"key":"2018112909360433000_43.8.1566.17","doi-asserted-by":"publisher","DOI":"10.1186\/2049-6958-6-3-183"},{"key":"2018112909360433000_43.8.1566.18","doi-asserted-by":"publisher","DOI":"10.1111\/j.1445-5994.2011.02702.x"},{"key":"2018112909360433000_43.8.1566.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2012.01.001"},{"key":"2018112909360433000_43.8.1566.20","doi-asserted-by":"publisher","DOI":"10.1007\/s12026-013-8408-9"},{"key":"2018112909360433000_43.8.1566.21","doi-asserted-by":"publisher","DOI":"10.1002\/art.38270"},{"key":"2018112909360433000_43.8.1566.22","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kev004"},{"issue":"Suppl 11","key":"2018112909360433000_43.8.1566.23","first-page":"S557","article-title":"Assessment of the effect of rituximab in the treatment of interstitial lung disease associated with the antisynthetase syndrome","volume":"66","author":"Doyle","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2018112909360433000_43.8.1566.24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197502132920706"},{"key":"2018112909360433000_43.8.1566.25","doi-asserted-by":"publisher","DOI":"10.1002\/art.21291"},{"key":"2018112909360433000_43.8.1566.26","doi-asserted-by":"publisher","DOI":"10.1002\/art.20349"},{"key":"2018112909360433000_43.8.1566.27","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-011-0176-8"},{"key":"2018112909360433000_43.8.1566.28","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.121026"},{"key":"2018112909360433000_43.8.1566.29","first-page":"436","article-title":"Calcineurin inhibitors in a cohort of patients with antisynthetase-associated interstitial lung disease","volume":"31","author":"Labirua-Iturburu","year":"2013","journal-title":"Clin Exp Rheumatol"},{"issue":"Suppl 11","key":"2018112909360433000_43.8.1566.30","first-page":"S552","article-title":"The early use of cyclosporine is beneficial for long-term prognosis in patients of polymyositis\/dermatomyositis-associated interstitial lung disease with antisynthetase antibodies","volume":"66","author":"Hosono","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2018112909360433000_43.8.1566.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2007.11.026"},{"key":"2018112909360433000_43.8.1566.32","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.176.10.6277"},{"key":"2018112909360433000_43.8.1566.33","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2567.2002.01417.x"},{"key":"2018112909360433000_43.8.1566.34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0011776"},{"key":"2018112909360433000_43.8.1566.35","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.181.3.1780"},{"key":"2018112909360433000_43.8.1566.36","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.179.1.26"},{"key":"2018112909360433000_43.8.1566.37","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20090585"},{"key":"2018112909360433000_43.8.1566.38","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M111.241786"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.150844","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,11,29]],"date-time":"2018-11-29T14:09:25Z","timestamp":1543500565000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.150844"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,1]]},"references-count":38,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2016,8,1]]},"published-print":{"date-parts":[[2016,8]]}},"alternative-id":["10.3899\/jrheum.150844"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.150844","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,1]]}}}